In older patients with AML prevention of relapse has remained one of the major therapeutic challenges with more than 75% relapses following complete remission (CR).
Introduction
The majority of patients with AML are 60 years of age or older. Older age is a major negative determinant of outcome in acute myeloid leukemia (AML), independent of the greater prevalence of unfavorable cytogenetic features in older patients. Long term survival (at 5 yrs) of intensively treated patients is in the order of 10% [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In those in whom intensive chemotherapy is applied for remission induction the complete response rate is on average in the range of 40-50%. It is striking that almost all remissions are subsequently lost within 3 years. There is a necessity to develop more active therapeutic regimens for the elimination of residual leukemia in remission and thereby stabilizing these remissions more effectively. The results of previous randomized studies concerned with the challenge of postremission treatment in patients aged 60 yrs and above have been highly unsatisfactory. Studies based upon the use of cytarabine according various dose intensification schedules did not produce therapeutic benefits. 11, 12 Two studies have produced an improvement of disease-free survival in a comparison between low-dose cytarabine and no maintenance chemotherapy but overall survival outcome was not different 3,13. A comparison between one additional cycle of combination chemotherapy for remission consolidation with 4 additional cycles showed no differences in survival 5 .
When 3 versus 4 successive cycles of intensive chemotherapy were directly compared no differences in outcome were noted , 10 . Also the use of interferon after CR did not result in any significant positive effect on outcome 5 . Two studies concerned with a comparison between one single intensive consolidation cycle in remission versus low dose chemotherapy delivered in an outpatient setting produced contradictory results 14, 15 The first study in complete responders after intensive chemotherapy that compared a single additional intensive cycle of chemotherapy during hospitalization with six repeated cycles of lower dose ambulatory combination chemotherapy , suggested a survival and disease free survival advantage at 2 years for the ambulatory regimen but whether this benefit was maintained during longer follow up remains to be seen 14 . The results of a second study of smaller size has suggested that one single additional intensive course of chemotherapy is better than a 1 year oral schedule of combination chemotherapy 15 High dose cytarabine while offering effective postremission treatment in young and middleaged adults appears too toxic in patients over the age of 60 and therefore the use of high GO has shown antileukemic activity in remission induction in patients with AML of older age [16] [17] [18] . GO is a conjugate of an anti-CD33 antibody and the toxin calicheamycin.
The application of GO targets CD33 antigen positive leukemic cells and following binding to the surface the toxin is internalized leading to cell death.
Here we present the results of a randomized cooperative group study in which after remission induction chemotherapy in first complete remission a maintenance regimen of 3 cycles of GO at 6 mg/m2 at 4 week intervals was compared with no further chemotherapy.
Patients and methods

Study design and treatment
Patients in the HOVON-43/SAKK/AMLSG study who had entered a complete remission (CR) after two cycles of remission induction chemotherapy had the option to be randomly assigned to three cycles of gemtuzumab ozogamicin (GO) at 6 mg/m 2 per 2-hour infusion at 4-week intervals or no further treatment. 19 The study had been approved by the ethics committees of the participating institutions and was conducted in accordance with the Declaration of Helsinki. All participants gave their informed consent.
HOVON-43 study is registered at Netherlands Trial Registry Number NTR212 and as ISRCTN77039377
Eligibility
Previously untreated patients with a cytopathologically confirmed diagnosis of AML (M0-M2 and M4-M7) and a minimum of 20% blast infiltrate in the bone marrow, and who were 61 years of age or more were eligible provided they had a WHO performance status of Patients with a concurrent other active malignancy or those previously treated with induction therapy for AML or MDS or those with AML following chronic myeloid leukemia, primary myelofibrosis or polycythemia rubra vera were not eligible nor were patients with severe heart, lung or neurological disease (for details see
19
). For randomisation postremission patients were required to have attained a CR and completed the first and second induction cycles with daunorubicin and cytarabine, serum bilirubin of less than 2 x normal value, hematological values of ANC above 1.5 x 109/l and platelets above 100 x 109/l.
Patient characteristics and classification
Based on the karyotype, patients were classified at diagnosis into distinct prognostic categories. Favorable risk applied to patients with core binding factor abnormalities (CBF) , i.e., with t(8;21) (q22;q22), inv (16) 19, 21 .
Patients without CBF abnormalities and without MK, but with abnormalities usually considered as unfavorable (complex, -5/7(q) , abn 3q, t(6;9), t (9;22) or abn 11q23) were classified as Unfavorable, while the remaining cytogenetic abnormalities were designated as "CA other" 19 . Therapy-related leukemias as well as leukemias following an antecedent hematological condition were classified as secondary AML. Presence of hepatomegaly and splenomegaly assessed on physical examination, WHO performance status, extramedullary disease, and white blood cell count (WBC) were registered at diagnosis.
Statistical analysis, criteria of response and evaluation of outcome
The primary objectives of the study were to assess in a randomized comparison the value of gemtuzumab ozogamicin (GO, anti-CD33-calicheamycin) as post remission therapy (in direct comparison to controls, ie no further chemotherapy) in older patients with AML and RAEB as regards the disease free survival. Secondary objectives were the evaluation of the effects of GO (gemtuzumab ozogamicin) therapy post remission with respect to toxicity, disease-free survival (DFS) with failure either relapse or death in first CR, the competing risk probabilities of relapse and death in first CR, and overall survival.
Complete response had been defined as a cellular marrow with less than 5 % blasts, no
Auer rods, no evidence of extramedullary leukemia, and peripheral granulocyte and platelet counts of at least 1.0 x10 9 /l and 100x10 9 /l, respectively. DFS and overall survival are measured from the time of postremission randomization until the occurrence of relapse or death (DFS), death (OS) or until censoring at last contact. Relapse is a recurrence of leukemia following a first complete remission.
We had expected that about 30% of all patients (or n=240) would be randomized between GO post remission treatment and no further treatment. This number of patients would give a power of 78% with a two-sided test at 5% significance level to detect an increase of the duration of disease free survival from second randomisation with 50%, which corresponds with a HR=0.67 and an expected 12 month DFS in the nonmaintenance arm of 40% compared with 54% in the GO post induction arm
All analyses are done according intention to treat irrespective of protocol compliance, but patients who were ineligible for randomization as they had not reached
For personal use only. on April 21, 2017 . by guest www.bloodjournal.org From CR (2 in the control group and 7 in the GO treatment group) and one patient (control arm) who was lost to follow-up since the date of randomization were excluded. The logrank test and Cox regression analysis were applied to analyze the differences between both groups with respect to overall survival and disease free survival. These analyses were done without and with adjustment for age and cytogenetic risk classification. All Pvalues reported are 2-tailed.
Results
Randomization to postremission treatment
Between October 27, 2000 and June 9, 2006 814 evaluable and eligible patients were entered in the study at diagnosis. Of 481 patients reaching complete remission on induction a total of 232 evaluable and eligible patients (30% of registered patients and 48 % of complete responders) were randomized for postremission treatment, ie 113 pts (15%) for GO and 119 pts (15%) for no further treatment. The median follow up time of patients still alive at the date of last contact since the date of postremission randomization was 45 months. The major reasons why patients in CR were not randomized included: poor performance status or residual organ toxicities after remission induction treatment (n= 53), incomplete platelet recovery or delayed hematopoietic recovery following remission induction therapy (n=28), death (n=41), relapse (n=21), choice for allogeneic (n=47) or autologous (n=5) hematopoietic stem cell transplantation, refusal (n=37), other/unclear (n=16) . One patient in CR was randomized but was lost to follow up since the date of randomization and has been excluded as not evaluable.
Of the patients assigned to GO or no postremission therapy, 70% had previously achieved CR already after remission induction cycle I (same for GO and control study arms).
Among the group assigned to GO 3 patients did not receive GO. Among the control patients none received GO but 1 patient received an allograft and 1 patient received an autologous stem cell graft. These patients are included in their respective arms for the analysis according intention to treat. Of the randomized patients 109 pts (47%) had received induction therapy with the 45 mg/m 2 dose schedule of daunorubicin (days 1,2,
3) and cytarabine (200 mg/m 2 days 1-7) and 123 (53%) patients had been induced with 
Postremission therapy
Of 113 patients assigned to the three monthly cycles of gemtuzumab ozogamicin (6 mg/mg 2 ) treatment 110 completed postremission cycle 1, 89 completed GO cycle 2 at a median interval of 30 days and 65 patients received the third cycle of GO after a median interval of 35 days after the second cycle.The reasons for not completing the GO treatment with 3 cycles were hematological cytopenia/bone marrow suppression/toxicity (n=27), relapse (n=12) and noncompliance (n=6).
Treatment outcome according postremission randomization and prognostic significance of cytogenetics
There were no differences in outcome (survival, disease free survival, relapse probability) between the two treatment arms (Table 2, Figure 1 ). Induction randomization between two dose levels of daunomycin (45 mg 
Toxicities
Median time towards neutrophil recovery (0.5 x 10 9 /L) after the GO cycles was 20 days (Table 3) . At day 30, 89% of patients had shown neutrophil recovery to a minimum value of 0.5x10 9 /L. The median time interval to platelet recovery (50x10
/L) was 14 days and
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Hematological recovery did not differ in relation to age or sequence number of GO cycle.
Fever developed in 43% of patients, and sepsis in 10%. Hepatic (bilirubin) toxicities were noted in 17% (CTC grade 2-4), and gastro-intestinal toxicities in 19% of patients (grades 2-4) of cases. There were 2 versus 7 deaths in CR in the control and GO treatment groups, respectively of which 1 versus 4 occurred during the first year (p=NS).
One patient died due to acute liver failure after a first cycle of GO treatment, an apparent toxic treatment related death. Another patient died from veno-occlusive disease, however not in first remission but after additional chemotherapy for relapse. He had attained a CR after cycle 1 and had relapsed at 20 months. He died at 25 months after diagnosis. A summary of toxicities is given in Table 3 . The actuarial nonrelapse mortality was slightly but nonsignificantly higher in the GO treatment arm (Table2)
Discussion
In general, complete remissions obtained following remission induction chemotherapy in patients of 60 years and older are short lived. This ultimately results in an overall survival probability of around 10% at 5 years from diagnosis [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In recent years various efforts have been undertaken in complete remission to prevent relapse but unfortunately these attempts have met with only limited success. Here we present the results of a prospective comparison with mature follow up (the median follow up of the patients still alive is 45 months, while 88% of these patients have a follow up longer than 2 years) regarding the use of gemtuzumab ozogamicin in complete remitters who had first received two induction cycles of intensive cytarabine-daunorubicin based chemotherapy (see 19 ).
Gemtuzumab ozogamicin was considered an interesting postremission agent as the drug as a single compound when given in two doses 14 days apart has shown clinical antileukemic activity in induction in older individuals with AML [16] [17] [18] . The current study was designed with a no further treatment arm as the comparator in order to allow for a absolute comparison. Thus we assumed that three successive cycles of GO when applied in complete remission, ie in conditions of subclinical disease, might exert a positive effect upon disease outcome. However, treatment results as regards any of the major
For personal use only. on April 21, 2017 . by guest www.bloodjournal.org From clinical endpoints (relapse probability, disease free survival, overall survival) between the GO postremission and no further treatment groups appear virtually identical. In the mean time a phase III study with another but naked anti-CD33 antibody (lintuzumab) applied in a different setting of induction therapy in patients with AML in relapse has neither shown indications of clinical improvements. 22 The use of GO as postremission treatment apparently added various hematological and organ toxicities, usually mild, although there was one death due to liver failure that was considered drug related ( Table 3 
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